HIV-infection
Conditions
Brief summary
A randomized single dose, drug-drug interaction study in healthy volunteers for VM - 1500 given alone or in combination with Raltegravir or Darunavir in a 3 arm approach. The parallel design is used due to the long half life for VM-1500.
Detailed description
This drug-drug interaction study will not be done as a cross-over study due to the extreme long half life of the drug. The 24 healthy subjects participating will be randomized to VM-1500 alone or VM-1500 in combination with Raltegravir or Darunavir in parallel arms. For the cohort taking VM-1500 40 mg only just 4 subject will be enrolled as 6 subjects have been already on the same regimen in the trial before. Based on the parallel design it seems appropriate not to expose more healthy subjects than necessary. This means the available data of 6 subjects dosed with 40 mg VM-1500 alone will be matched. Three groups of healthy subjects will be randomized to VM-1500 alone or VM-1500 in combination with Raltegravir or Darunavir (4:10:10). The healthy subjects will stay at the unit and receive 40 mg VM-1500 alone or VM1500 in combination with Raltegravir or Darunavir one time and PK blood samples at several time points will be collected. PK (trough level) blood samples will also be collected at visits on Days 2, 4,7, 14, 21, and on Day 36.
Interventions
DRUGVM-1500
VM-1500 40 mg
DRUGDarunavir
Darunavir 600 mg
DRUGRitonavir
Ritonavir 100 mg
DRUGRaltegravir
400 mg Raltegravir
Sponsors
Viriom
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male subjects age between 18-45 years 2. Has been determined healthy by physical examination, assessment of drug abuse, medical history and vital signs 3. Has normal or acceptable results for the following screening tests: complete blood count (CBC), blood urea nitrogen (BUN), serum creatinine (Cr), fasting blood sugar (FBS), total bilirubin, aspartate aminotransferase (AST or SGOT), alanine aminotransferase (ALT or SGPT), alkaline phosphatase (ALP) and urinalysis. 4. Negative result for hepatitis A, hepatitis B, hepatitis C and HIV antibodies 5. Willing to participate and signed the informed consent form
Exclusion criteria
1. Hepatic or kidney disorders or any other disease or disorder which may in the opinion of the Investigator interfere with the results of the study or threaten the health of volunteers; 2. Drug intake (including herbal drugs) during the last month; 3. Active alcohol and/or drug abuse that, in the opinion of the site investigator, would interfere with adherence to study requirements; 4. Volunteers have taken any investigational drug at least 3 month prior to the start of the study; 5. Inability to understand the Protocol or follow its instructions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events as assessed by Division of AIDS table for grading the severity of ADULT Adverse Events | 36 days | Safety and tolerability of VM-1500 alone or in combination with raltegravir or darunavir in adult healthy subjects |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma concentrations of VM-1500 from Day 1 to Day 36 | 36 days | Plasma concentrations of VM-1500 given alone or in combination with raltegravir or darunavir |
| Plasma concentrations of VM1500A (active metabolite of VM1500) from Day 1 to Day 36 | 36 days | Plasma concentrations of VM-1500A alone or in combination with raltegravir or darunavir |
Countries
Thailand
Outcome results
None listed